These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 444281)

  • 1. Effect of a catechol-O-methyl transferase inhibitor, U-0521, with levodopa administration.
    Fahn S; Comi R; Snider SR; Prasad AL
    Biochem Pharmacol; 1979 Apr; 28(7):1221-5. PubMed ID: 444281
    [No Abstract]   [Full Text] [Related]  

  • 2. Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.
    Reches A; Jiang D; Fahn S
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):34-7. PubMed ID: 7121609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of brain serotonin by L-tryptophan in levodopa-treated rats.
    Fahn S; Snider S; Prasad AL; Lane E; Makadon H
    Neurology; 1975 Sep; 25(9):861-5. PubMed ID: 1172210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice.
    Törnwall M; Tuomainen P; Männistö PT
    Arch Int Pharmacodyn Ther; 1992; 320():5-20. PubMed ID: 1300941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum.
    Reches A; Jiang D; Fahn S
    Biochem Pharmacol; 1982 Nov; 31(21):3415-8. PubMed ID: 7150363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT; Tuomainen P; Tuominen RK
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects.
    Bieck PR; Nilsson E; Antonin KH
    J Neural Transm Suppl; 1990; 32():387-91. PubMed ID: 2128511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
    Törnwall M; Kaakkola S; Tuomainen P; Kask A; Männistö PT
    Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase.
    Nuutila J; Kaakkola S; Männistö PT
    J Neural Transm; 1987; 70(3-4):233-40. PubMed ID: 2960778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of L-DOPA on brain polysomes and protein synthesis: probable mediation by intracellular dopamine.
    Weiss BF; Roel LE; Munro HN; Wurtman RJ
    Adv Neurol; 1974; 5():87-99. PubMed ID: 4155238
    [No Abstract]   [Full Text] [Related]  

  • 13. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.
    Cumming P; Boyes BE; Martin WR; Adam M; Ruth TJ; McGeer EG
    Biochem Pharmacol; 1987 Aug; 36(15):2527-31. PubMed ID: 3111485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats.
    Brannan T; Martínez-Tica J; Yahr MD
    Neurology; 1992 Mar; 42(3 Pt 1):683-5. PubMed ID: 1549240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
    Parada A; Soares-da-Silva P
    Pharmacology; 2003 May; 68(1):29-37. PubMed ID: 12660477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 4-o-methyl metabolites of catecholamines. Homo-iso-vanillic acid in rat urine and brain; urinary iso-vanyl compounds after intraperitoneal administration of dopamine and of dopamine precursors and derivatives.
    Mathieu P; Charvet JC; Greffe J
    Biochem Pharmacol; 1975 Jan; 24(1):43-8. PubMed ID: 1122261
    [No Abstract]   [Full Text] [Related]  

  • 17. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons.
    Storch A; Blessing H; Bareiss M; Jankowski S; Ling ZD; Carvey P; Schwarz J
    Mol Pharmacol; 2000 Mar; 57(3):589-94. PubMed ID: 10692500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in rats.
    Karoum F; Freed WJ; Chuang LW; Cannon-Spoor E; Wyatt RJ; Costa E
    Brain Res; 1988 Feb; 440(1):190-4. PubMed ID: 3129126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-dopa in the rat.
    Waldmeier PC; De Herdt P; Maitre L
    J Neural Transm Suppl; 1990; 32():381-6. PubMed ID: 2128510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Acetyl, 4-O-methyldopa, a major metabolite of L-4-O-methyldopa in man and rat.
    Mathieu P; Greffe J; Deruaz D; Guilluy R; Gjessing L
    Biochem Pharmacol; 1976 Mar; 25(5):497-500. PubMed ID: 942485
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.